Clinical expansion Inimmune is expanding its clinical portfolio beyond INI-4001 in oncology into allergic asthma and food allergy, signaling opportunities to partner on clinical development, companion diagnostics, or translational research collaborations.

Vaccine delivery focus Active participation in the World Vaccine Congress and a leadership role in next-generation adjuvant systems for mucosal delivery indicate potential for partnerships around adjuvant technology, regulatory strategy support, and collaborative vaccine programs.

Montana footprint Headquartered and advancing operations in Missoula, MT with recent CMO and finance hires suggests a growing local ecosystem play; BD efforts could align with regional talent, contract research, and site-level partnerships.

Funding and status Current revenue estimated between 10-25 million with 23 million in funding and a clinical-stage focus create opportunities for strategic partnerships, co-development deals, and milestone-driven collaborations to de-risk early programs.

Immunotherapy focus A portfolio centered on next-generation immunotherapies and innate immune modulation, including a TLR7/8 agonist in Phase 1, presents avenues for scientific collaboration, investigator-initiated studies, and technology licensing.